<DOC>
	<DOCNO>NCT00004695</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether polyethylene-glycol-conjugated interleukin 2 ( PEG-IL-2 ) reduce number infection patient common variable immunodeficiency . II . Determine whether therapy improve lung function patient pulmonary impairment .</brief_summary>
	<brief_title>Randomized Study Polyethylene-Glycol-Conjugated Interleukin 2 Patients With Common Variable Immunodeficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , open-label study . Patients randomized receive polyethylene-glycol-conjugated interleukin 2 ( PEG-IL-2 ) placebo . Patients receive PEG-IL-2 placebo subcutaneous injection weekly 18 month . Patients maintain daily diary 24 month . Patients follow every 4 month 2 year . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Documented common variable immunodeficiency define reduction serum IgG least 2 standard deviation In vitro lymphocyte proliferative response PEGIL2 least 10 time unstimulated culture Prior/Concurrent Therapy No biologic response modifier therapy ( i.e. , interferon , cyclosporin A ) except prednisone ( maximum 10 mg/day ) Concurrent treatment dosage intravenous gammaglobulin least 6 month require Patient Characteristics Life expectancy : At least 24 month Other : Not pregnant nursing HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>common variable immunodeficiency</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>primary immunodeficiency disease</keyword>
	<keyword>rare disease</keyword>
</DOC>